| BCBS Highmark Delaware | Treatment of Benign or Premalignant Skin Conditions | 2025-05-05 |
| BCBS Highmark NY and West NY | Tonic Motor Activation System (TOMAC) | 2025-05-05 |
| BCBS Highmark NY and West NY | Treatment of Benign or Premalignant Skin Conditions | 2025-05-05 |
| Aetna | Inflammatory Bowel Disease: Serologic Markers and Pharmacogenomic and Metabolic Assessment of Thiopurine Therapy | 2025-05-01 |
| UHC Medicare Advantage | Positron Emission Tomography (PET) Scan for Myocardial Imaging - Medicare Advantage Medical Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Crysvita® (Burosumab-Twza) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Parsabiv® (Etelcalcetide) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Tzield® (Teplizumab-Mzwv) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC Surest Medical and Drug | Crysvita® (Burosumab-Twza) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC Surest Medical and Drug | Parsabiv® (Etelcalcetide) – Commercial Medical Benefit Drug Policy | 2025-05-01 |